Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4808723 | 0.94 | RAB9A (0.41) | RAB9ANPC1SMN1; SMN2NPSR1MAPT | |
| SCHEMBL4806545 | 0.92 | MEN1 (0.42) | OPRK1RAB9AADAM17NPC1L3MBTL1 | |
| SCHEMBL4817586 | 0.90 | ADAM17 (0.43) | ADAM17SMN1; SMN2 | |
| SCHEMBL4809655 | 0.90 | RAB9A (0.43) | OPRK1RAB9ANPC1L3MBTL1SMN1; SMN2 | |
| SCHEMBL4812200 | 0.89 | RAB9A (0.41) | OPRK1RAB9ANPC1L3MBTL1SMN1; SMN2 | |
| SCHEMBL4808773 | 0.88 | ADAM17 (0.41) | OPRK1RAB9AADAM17NPC1SMN1; SMN2 | |
| SCHEMBL4808768 | 0.88 | ADAM17 (0.41) | RAB9AADAM17NPC1SMN1; SMN2 | |
| SCHEMBL4815578 | 0.87 | SMN1; SMN2 (0.42) | RAB9ANPC1L3MBTL1SMN1; SMN2NPSR1 | |
| SCHEMBL4810961 | 0.86 | TP53 (0.39) | RAB9AADAM17NPC1L3MBTL1SMN1; SMN2 | |
| SCHEMBL4805258 | 0.85 | SMN1; SMN2 (0.41) | RAB9ANPC1L3MBTL1SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388103-B2 | Cyclopentane carboxylate compounds, process and intermediates for preparing the same and use thereof | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2008-06-17 | — | — | US | disclosed |
| US-20060094843-A1 | Cyclopentane carboxylate compounds, process and intermediates for preparing the same and use thereof | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2006-05-04 | — | — | US | disclosed |
| WO-2006045246-A1 | CYCLOPENTANE CARBOXYLATE COMPOUNDS, PROCESS AND INTERMEDIATES FOR PREPARING THE SAME AND USE THEREOF | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094843-A1 | Cyclopentane carboxylate compounds, process and intermediates for preparing the same and use thereof | C5, C1S, AKR1C3 | OPRK1 1007/4885RAB9A 3676/4885ADAM17 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.